10x Genomics Appoints Kim Popovits to Board of Directors
April 02 2020 - 9:00AM
10x Genomics, Inc. (Nasdaq: TXG) today announced the appointment of
Kim Popovits, former Chairman of the Board, President and Chief
Executive Officer of Genomic Health, Inc., to the company’s Board
of Directors. She brings decades of experience in scaling
organizations, building global operations and advancing innovations
in both the diagnostics and pharmaceutical industries.
“Kim has been a leader and a pioneer in introducing
new technologies into the healthcare system impacting the lives of
countless patients during her time at Genomic Health and
Genentech,” said Serge Saxonov, co-founder and CEO of 10x Genomics.
“Today, more than ever, we need to enable scientists to make
discoveries that will lead to better patient outcomes, and we are
excited to have Kim join the Board to accelerate our
efforts.”
Kim arrived at Genomic Health in 2002 as President
and Chief Operating Officer, before becoming CEO in 2009 and
Chairman of the Board in 2012. Under her leadership, Genomic Health
became the industry leader in genomic-based diagnostic tests that
address both the overtreatment and optimal treatment of cancer,
resulting in an acquisition by Exact Sciences (Nasdaq: EXAS) in
November 2019.
Prior to joining Genomic Health, Kim held several
management roles at Genentech, Inc. including Senior Vice President
of Marketing and Sales where she led the commercialization of 14
new therapies in the biotechnology industry. Before Genentech, Kim
was at American Critical Care, a Division of American Hospital
Supply, a supplier of healthcare products to hospitals.
“I am excited to be joining a team that is leading
the advancement of science at a pace that will transform clinical
practice and lead to better outcomes for patients,” said Popovits.
“The track record of the 10x team in delivering innovations to our
industry is impressive and I look forward to applying my background
towards enhancing the continued success of the company.”
In addition to her Board position at 10x Genomics,
Kim is a current member of the Boards of Directors for Kiniksa
Pharmaceuticals, Ltd. and MyoKardia, Inc., and previously served on
the Board of ZS Pharma Inc.
About 10x Genomics10x Genomics is
a life science technology company building products to interrogate,
understand and master biology to advance human health. The
company’s integrated solutions include instruments, consumables and
software for analyzing biological systems at a resolution and scale
that matches the complexity of biology. 10x Genomics products have
been adopted by researchers around the world including 97 of the
top 100 global research institutions and 19 of the top 20 global
pharmaceutical companies, and have been cited in over 700 research
papers on discoveries ranging from oncology to immunology and
neuroscience. The company's patent portfolio comprises more than
700 issued patents and patent applications.
Forward Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 as
contained in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements generally can be identified by the use
of forward-looking terminology such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project” “contemplate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or the negatives of these terms or
variations of them or similar terminology. These
forward-looking statements involve risks and uncertainties that
could cause 10x Genomics, Inc.’s actual results to differ
materially from the anticipated results and expectations expressed
in these forward-looking statements. These statements are based on
management’s current expectations, forecasts, beliefs, assumptions
and information currently available to management, and actual
outcomes and results could differ materially from these statements
due to a number of factors. These and additional risks and
uncertainties that could affect 10x Genomics, Inc.’s financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
10x Genomics, Inc. files with the Securities and Exchange
Commission from time to time. The forward-looking statements in
this press release are based on information available to 10x
Genomics, Inc. as of the date hereof, and 10x Genomics, Inc.
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing 10x Genomics, Inc.’s
views as of any date subsequent to the date of this press
release.
Disclosure Information10x Genomics
uses filings with the Securities and Exchange Commission, its
website (www.10xgenomics.com), press releases, public conference
calls, public webcasts and its social media accounts as means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD.
ContactsInvestors:investors@10xgenomics.comMedia:media@10xgenomics.com
EXACT Sciences (NASDAQ:EXAS)
Historical Stock Chart
From Mar 2024 to Apr 2024
EXACT Sciences (NASDAQ:EXAS)
Historical Stock Chart
From Apr 2023 to Apr 2024